Search / Trial NCT06225921

Neoadjuvant Adebrelimab With Dalpiciclib for Resectable Esophageal Squamous Cell Carcinomas

Launched by WEST CHINA HOSPITAL · Jan 25, 2024

Trial Information

Current as of October 03, 2024

Recruiting

Keywords

Esophageal Squamous Cell Carcinoma Neoadjuvant Therapy Immunotherapy Cdk4/6 Inhibitor

Description

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Patients diagnosed with esophageal squamous cell cancer by gastroscopic biopsies.
  • * The primary tumor should be located in the thorax.
  • * The patients should be evaluated to be able to have surgical resection before the surgery according to the examinations .
  • 2. The patients should be at the range of 18-75 years old, Eastern Cooperative Oncology Group (ECOG) 0-1.
  • 3. The patients should be able to understand our research and be willing to accept surgical treatment and sign the informed consent.
  • Exclusion Criteria:
  • 1. The stage of tumor is T4b (AJCC/International Union Against Cancer (UICC) 8th Edition) and cannot be resected.
  • 2. Currently undergoing other chemotherapy, radiotherapy, targeted therapy or immunotherapy.
  • 3. History of other malignancies.
  • 4. Have an active autoimmune disease requiring systemic treatment or a documented history of clinically severe autoimmune disease.
  • 5. Any history of allergic disease, or a sever hypersensitivity reaction to drugs, or allergy to the study drug components.
  • 6. Presence of serious medical diseases, such as grade II and above cardiac dysfunction (NYHA criteria), ischemic heart diseases, etc.
  • 7. The patients with severe systematic intercurrent diseases, including active infection or poorly controlled diabetes, coagulation disorders, hemorrhagic tendency, or those undergoing thrombolysis or anticoagulant therapy, are excluded from the study.
  • 8. Female participants who test positive for a serum pregnancy test, are in the lactation period, or are at a childbearing stage and unwilling to use contraception measures during the research are excluded.
  • 9. Received any investigational drug within 4 weeks prior to the first dose, or concurrently enrolled in another clinical trial.
  • 10. Any other factors that are not suitable for inclusion in this study judged by investigators.

About Sponsor

The National Institute of Allergy and Infectious Diseases (NIAID, /ˈnaɪ.æd/) is one of the 27 institutes and centers that make up the National Institutes of Health (NIH), an agency of the United States Department of Health and Human Services (HHS). NIAID's mission is to conduct basic and applied research to better understand, treat, and prevent infectious, immunologic, and allergic diseases.

Contacts

JC

Jennifer Cobb

Immunology at National Institute of Allergy and Infectious Diseases (NIAID)

Locations

Chengdu, Sichuan, China

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0